279,426 results match your criteria lymphoma central

Mortality predictive factors of People Living with Human-immunodeficiency-virus and Bloodstream Infection.

Int J Infect Dis 2021 Jun 20. Epub 2021 Jun 20.

Internal Medicine department, Coimbra Hospital and University Center, Coimbra, Portugal; Faculty of Medicine, University of Coimbra. Electronic address:

Introduction: Portugal had one of the highest people living with human-immunodeficiency-virus (PLWHIV) mortality rates in Europe, although it is declined after antiretroviral therapy introduction such as bloodstream infections (BSI) mortality in these patients. However BSI mortality is still high and with few European data. So, characterizing BSI and defining prognostic factors may improve our approach. Read More

View Article and Full-Text PDF

Dismal outcome of relapsed or primary refractory adult T-cell lymphoblastic lymphoma: A retrospective study from China.

Asia Pac J Clin Oncol 2021 Jun 23. Epub 2021 Jun 23.

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

Aim: Little is known about the outcome and prognostic factors of relapsed or refractory T-cell lymphoblastic lymphoma (T-LBL), especially in adult patients. The aim of this study was to analyze the characteristics, outcome and prognostic factors for this patient population.

Methods: Between January 2006 and December 2017, we retrospectively analyzed 84 adult patients with T-LBL, and 44 relapsed or primary refractory patients were included in this analysis. Read More

View Article and Full-Text PDF

Monocarboxylate transporter antagonism reveals metabolic vulnerabilities of viral-driven lymphomas.

Proc Natl Acad Sci U S A 2021 Jun;118(25)

Department of Molecular Genetics and Microbiology, Duke Center for Virology, Duke University School of Medicine, Durham, NC 27710;

Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that typically causes asymptomatic infection but can promote B lymphoid tumors in the immune suppressed. In vitro, EBV infection of primary B cells stimulates glycolysis during immortalization into lymphoblastoid cell lines (LCLs). Lactate export during glycolysis is crucial for continued proliferation of many cancer cells-part of a phenomenon known as the "Warburg effect"- and is mediated by monocarboxylate transporters (MCTs). Read More

View Article and Full-Text PDF

Endoscopic endonasal approach to the cavernous sinus Epstein-Barr virus-positive B cell non-Hodgkin lymphoma in a child: case report.

Childs Nerv Syst 2021 Jun 23. Epub 2021 Jun 23.

Department of Neurosurgery, Gulhane School of Medicine, University of Health Sciences, Ankara, Turkey.

Cavernous sinus (CS) lymphoma without paranasal sinuses involvement is extremely rare in pediatric population and remains a diagnostic challenge due to its similarity to other tumors located in this area. An 8-year-old boy presented with a 6-day history of gradually developing ptosis in the right eyelid. After admission, his symptoms progressed within 24 h to include right-sided ophthalmoplegia consisting of oculomotor and abducens nerve palsies. Read More

View Article and Full-Text PDF

[Lymphoma in children and adolescents].

Radiologe 2021 Jun 23. Epub 2021 Jun 23.

Institut für Kinderradiologie, Universitätsklinikum Leipzig, Liebigstraße 20a, 04103, Leipzig, Deutschland.

Clinical/methodological Issue: Lymphoma is the third most common neoplasm in children. Detection, accurate staging, and restaging are important for all radiologists involved in the diagnosis of children.

Standard Radiological Methods: Magnetic resonance imaging (MRI), positron emission tomography/computed tomography (PET/CT), CT, ultrasound, X‑ray. Read More

View Article and Full-Text PDF

An unusual extranodal natural killer/T-cell lymphoma presenting as chronic laryngitis: A case report.

Medicine (Baltimore) 2021 Jun;100(25):e26314

Service of Rheumatology, Hospital Clínico de la Universidad de Chile, Santiago de Chile.

Rationale: Nasal-type, extranodal natural killer (NK)/T-cell lymphoma is a rare lymphoma. The tumor usually shows ulcerative and necrotic lesions in the nasal cavities and sinuses. Tissue involvement outside the nasal cavity is uncommon. Read More

View Article and Full-Text PDF

Functional Phenotype Flow Cytometry: On Chip Sorting of Individual Cells According to Responses to Stimuli.

Adv Biol (Weinh) 2021 Jun 23:e2100220. Epub 2021 Jun 23.

Living Systems Institute, University of Exeter, Stocker Road, Exeter, EX4 4QD, UK.

The ability to effectively separate and isolate biological cells into specific and well-defined subpopulations is crucial for the advancement of our understanding of cellular heterogeneity and its relevance to living systems. Here is described the development of the functional phenotype flow cytometer (FPFC), a new device designed to separate cells on the basis of their in situ real-time phenotypic responses to stimuli. The FPFC performs a cascade of cell processing steps on a microfluidic platform: introduces biological cells one at a time into a solution of a biological reagent that acts as a stimulus, incubates the cells with the stimulus solution in a flow, and sorts the cells into subpopulations according to their phenotypic responses to the provided stimulus. Read More

View Article and Full-Text PDF

Association between the IL-1A, IL-1B and IL-1R polymorphisms and lymphoma.

Nucleosides Nucleotides Nucleic Acids 2021 Jun 23:1-13. Epub 2021 Jun 23.

Department of Human Anatomy and Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.

We investigate the impact of IL-1A, IL-1B and IL-1R1 polymorphism on lymphoma. This study consisted of 155 Non-Hodgkin's lymphoma (NHL) patients 55 Hodgkin's lymphoma (HL) patients and 150 healthy individuals. PCR-RFLP method and ARMS PCR were used for genotyping of IL-1A rs3783553, IL-1B rs3917356, rs16944, IL-1R1 rs10490571 and IL-1A rs3783550 polymorphism. Read More

View Article and Full-Text PDF

Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.

Leuk Lymphoma 2021 Jun 23:1-10. Epub 2021 Jun 23.

Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.

We retrospectively analyzed 38 patients with AML who received azacitidine (AZA) to treat disease relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients with objective response (OR) ( = 20) after AZA had significantly higher 2-year overall survival (OS) (45.0% vs 5. Read More

View Article and Full-Text PDF

Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.

Leuk Lymphoma 2021 Jun 23:1-13. Epub 2021 Jun 23.

BeiGene USA, Inc, San Mateo, CA, USA.

This report summarizes a totality-of-evidence approach supporting recommendation of a 320-mg total daily dose, either as 160-mg twice daily (BID) or 320-mg once daily (QD) for zanubrutinib in patients with mantle cell lymphoma. Data were derived from a phase 2 study in patients receiving 160-mg BID and a phase 1/2 study with similar response rates observed with 160-mg BID or 320-mg QD. Given the limited number of patients in the QD dose group, population pharmacokinetics and exposure-response analyses were employed to bridge the two regimens. Read More

View Article and Full-Text PDF

Application of mid-infrared microscopic imaging for the diagnosis and classification of human lymphomas.

J Biophotonics 2021 Jun 23:e202100079. Epub 2021 Jun 23.

Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria.

Mid-infrared (MIR) microscopic imaging of indolent and aggressive lymphomas was performed including formalin-fixed and paraffin-embedded samples of six follicular lymphomas and 12 diffuse large B-cell-lymphomas as well as reactive lymph nodes to investigate benefits and challenges for lymphoma diagnosis. MIR images were compared to defined pathological characteristics such as indolent versus aggressive versus reactive, germinal center versus activated cell-of-origin (COO) subtypes, or a low versus a high proliferative index and level of PD-L1 expression. We demonstrated that MIR microscopic imaging can differentiate between reactive lymph nodes, indolent and aggressive lymphoma samples. Read More

View Article and Full-Text PDF

A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.

Thorac Cancer 2021 Jun 23. Epub 2021 Jun 23.

Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan.

Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangements are found in ~ 5% of patients with non-small cell lung cancer (NSCLC). Several tyrosine kinase inhibitors (TKIs) have been developed for treatment of so-called ALK-positive NSCLC. In cases of tumor progression during treatment with second-generation ALK-TKIs, such as alectinib, brigatinib, or ceritinib, National Comprehensive Cancer Network guidelines propose a switch to lorlatinib, a third-generation ALK-TKI, or to cytotoxic chemotherapy. Read More

View Article and Full-Text PDF

Phase 2 Study of Tazemetostat for Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma with EZH2 Mutation in Japan.

Cancer Sci 2021 Jun 22. Epub 2021 Jun 22.

Department of Hematology and Rheumatology, Kindai University Hospital, Osaka, Japan.

Tazemetostat is a selective, reversible, small-molecule inhibitor of the histone methyltransferase enzyme, enhancer of zest homolog 2 (EZH2). In this multicenter, open-label, phase 2 study, we assessed the efficacy and safety of tazemetostat in Japanese patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) harboring the EZH2 mutation. Tazemetostat (800 mg BID) was orally administered (28-day cycle) until disease progression or unacceptable toxicity. Read More

View Article and Full-Text PDF

A preliminary study using spinal MRI-based radiomics to predict high-risk cytogenetic abnormalities in multiple myeloma.

Radiol Med 2021 Jun 22. Epub 2021 Jun 22.

Department of Radiology, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, 100191, People's Republic of China.

Objectives: We aimed to investigate the feasibility of predicting high-risk cytogenetic abnormalities (HRCAs) in patients with multiple myeloma (MM) using a spinal MRI-based radiomics method.

Materials And Methods: In this retrospective study, we analyzed the radiomic features of 248 lesions (HRCA [n = 111] and non-HRCA [n = 137]) using T1WI, T2WI, and fat suppression T2WI. To construct the radiomics model, the top nine most frequent radiomic features were selected using logistic regression (LR) machine-learning processes. Read More

View Article and Full-Text PDF

The protective effects of exogenous spermine on renal ischemia-reperfusion injury in rats.

Transl Androl Urol 2021 May;10(5):2051-2066

Department of Urology, Guizhou Provincial People's Hospital, Medical College of Guizhou University, Guiyang, China.

Background: To investigate the protective effects of exogenous spermine on renal ischemia-reperfusion injury in rats.

Methods: (I) Different doses of spermine were injected into rats to determine the safe dose on the kidneys. Kidney toxicity was assessed by hematoxylin and eosin (HE) staining of kidney tissue and enzyme-linked immunosorbent assay (ELISA) detection of neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) in the venous blood. Read More

View Article and Full-Text PDF

Long-Term Remission After Matched Sibling Donor Hematopoietic Cell Transplantation in a Patient With Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma.

Cureus 2021 May 20;13(5):e15132. Epub 2021 May 20.

Hematology and Oncology, Moffitt Cancer Center, Tampa, USA.

Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (CD8+ PCAECTL) is an extremely rare neoplasm with a poor prognosis. Chemotherapy typically does not result in a sustained response, and hematopoietic stem cell transplant (HSCT) is the only therapy that has been shown to produce a durable response of any kind. Here, we report a case of a 25-year-old previously healthy male who presented with a painful ulcerative lesion on the bottom of his right great toe and local lymphadenopathy. Read More

View Article and Full-Text PDF

A Rare Presentation of Acute Respiratory Distress Due to Diffuse Large B-Cell Lymphoma of the Tongue Base.

Cureus 2021 May 19;13(5):e15124. Epub 2021 May 19.

Otolaryngology - Head and Neck Surgery, Henry Ford Health System, Detroit, USA.

Primary diffuse large B-cell lymphoma of the tongue base (BOT) is an extremely rare entity with only a few cases described in the English literature to date. The incidence of BOT non-Hodgkin's lymphoma (NHL) increases with age, most commonly after the sixth decade of life with no observed gender differences. Our patient presented with a six-month history of right neck swelling, one-month history of dysphagia, a change in voice, and ultimately acute airway distress, which led to a tracheostomy. Read More

View Article and Full-Text PDF

Renal Lymphoma Mimicking a Retroperitoneal Hematoma.

Cureus 2021 May 18;13(5):e15099. Epub 2021 May 18.

Radiology, Hospital Beatriz Ângelo, Loures, PRT.

We report the case of a 65-year-old female with an atypical presentation of renal lymphoma at computed tomography (CT), which was initially misinterpreted as a retroperitoneal hematoma. This case highlights the importance to keep a high level of suspicion in order to make a prompt diagnosis since treatment strategies differ significantly. Read More

View Article and Full-Text PDF

Multifocal precursor B-cell lymphoblastic lymphoma in an infant with cardiac involvement: A case report.

Radiol Case Rep 2021 Aug 8;16(8):2054. Epub 2021 Jun 8.

Department of Radiology, Ha Noi Medical University, Ha Noi, Vietnam.

Lymphoma with cardiac involvement is a high-risk lesion, especially in children. We report a rare clinical case of multifocal precursor B-cell lymphoblastic lymphoma in a child with cardiac involvement. A 4-year-old boy presented to the Vietnam National Children's Hospital with a vague headache, but magnetic resonance imaging of the head was normal. Read More

View Article and Full-Text PDF

Ileal inflammatory pseudotumor in adolescent male patient with prior Burkitt lymphoma: A challenging diagnosis.

Radiol Case Rep 2021 Aug 8;16(8):2047-2052. Epub 2021 Jun 8.

Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy.

Inflammatory pseudotumor is a rare benign mesenchymal pediatric neoplasm, that can mimic tumoral residue or relapse at metabolic imaging with nonspecific clinical presentation and difficult diagnosis. We present the case of a 14year old male patient with fever of unknown origin and large ileal mass, diagnosed with and treated for Burkitt lymphoma, who performed several 18-fluoro-deoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) scans, during and after first line chemotherapy, showing persistent and focal uptake, while ileal mass volume decreased dramatically and the patient was clinically asymptomatic. Histopathological analysis of residual ileal mass was suggestive for xanthomatous pseudotumor, a type of inflammatory pseudotumor. Read More

View Article and Full-Text PDF

T lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association.

Ecancermedicalscience 2021 22;15:1221. Epub 2021 Apr 22.

Department of Histopathology, The Children's Hospital & Institute of Child Health, Ferozepur Road, Lahore 54400, Pakistan.

Lymphoblastic lymphoma and chronic myeloid leukaemia (CML) are two distinct neoplasms with different pathogenesis and clinical presentation. We hereby share a challenging case of a child presenting with fever, leucocytosis, generalised lymphadenopathy and massive splenomegaly. He was diagnosed as having novel association of concurrent T-lymphoblastic lymphoma diagnosed on cervical lymph node biopsy with BCR-ABL negative CML on bone marrow aspirate. Read More

View Article and Full-Text PDF

Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.

Cancer Gene Ther 2021 Jun 22. Epub 2021 Jun 22.

Human Genetics Research Center, Tehran, Iran., Baqiyatallah University of Medical Sciences, Tehran, Iran.

Chimeric antigen receptor (CAR) T-cell therapy is an encouraging and fast-growing platform used for the treatment of various types of tumors in human body. Despite the recent success of CAR T-cell therapy in hematologic malignancies, especially in B-cell lymphoma and acute lymphoblastic leukemia, the application of this treatment approach in solid tumors faced several obstacles resulted from the heterogeneous expression of antigens as well as the induction of immunosuppressive tumor microenvironment. Oncolytic virotherapy (OV) is a new cancer treatment modality by the use of competent or genetically engineered viruses to replicate in tumor cells selectively. Read More

View Article and Full-Text PDF

SOX11 inhibitors are cytotoxic in mantle cell lymphoma.

Clin Cancer Res 2021 Jun 22. Epub 2021 Jun 22.

Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai

Purpose: Mantle Cell Lymphoma (MCL) is a fatal subtype of Non-Hodgkin's Lymphoma. SOX11 transcription factor is overexpressed in the majority of nodal MCL. We have previously reported that B-cell specific overexpression of SOX11 promotes MCL pathogenesis via critically increasing BCR signaling in vivo. Read More

View Article and Full-Text PDF

SHP2 inhibition enhances the effects of tyrosine kinase inhibitors in preclinical models of treatment-naïve ALK-, ROS1-, or EGFR-altered non-small-cell lung cancer.

Mol Cancer Ther 2021 Jun 22. Epub 2021 Jun 22.

Department of Allergy and Respiratory Medicine, Okayama University Hospital.

After molecular-targeted therapy, some cancer cells may remain that are resistant to therapies targeting oncogene alterations, such as those in the genes encoding the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) as well as c-ros oncogene 1 (ROS1). The mechanisms underlying this type of resistance are unknown. Here we report the potential role of Src homology 2 domain-containing phosphatase 2 (SHP2) in the residual cells of ALK/ROS1/EGFR-altered non-small-cell lung cancer (NSCLC). Read More

View Article and Full-Text PDF

Targeting TfR1 with the ch128.1/IgG1 antibody inhibits EBV driven lymphomagenesis in immunosuppressed mice bearing EBV+ human primary B-cells.

Mol Cancer Ther 2021 Jun 22. Epub 2021 Jun 22.

Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA.

Epstein-Barr virus (EBV) is a human gammaherpesvirus associated with the development of hematopoietic cancers of B-lymphocyte origin, including AIDS-related non-Hodgkin lymphoma (AIDS-NHL). Primary infection of B-cells with EBV results in their polyclonal activation and immortalization. The transferrin receptor 1 (TfR1), also known as CD71, is important for iron uptake and regulation of cellular proliferation. Read More

View Article and Full-Text PDF

Extranodal NK/T cell lymphoma, nasal type: a rare diagnosis with common nasal presentation.

BMJ Case Rep 2021 Jun 22;14(6). Epub 2021 Jun 22.

Pathology, Pusat Perubatan Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.

A 39-year-old man presented with bilateral nasal obstruction for 4 months and associated with hyposmia and foul-smelling nasal discharge. Nasal endoscopy showed irregular mucosa of the nasal cavity with easily bleeding. Nasal biopsy reported as extranodal Natural Killer/T cell lymphoma, nasal type. Read More

View Article and Full-Text PDF

Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.

J Immunother Cancer 2021 Jun;9(6)

Medical Biochemistry and Molecular Biology and Immunology, Virgen Macarena University Hospital, Sevilla, Seville, Spain

Background: The search for immunological markers with ability of predicting clinical outcome is a priority in lymphomas, and in cancer in general. It is well known that some immunomodulatory cells, such as myeloid derived suppressor cells (MDSCs) or regulatory T cells (Tregs), are recruited by tumors, jeopardizing antitumor immunosurveillance. In this work, we have studied blood levels of these immunosuppressive cells in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), prior to and along the course of the experimental rituximab, gemcitabine, dexamethasone, and cisplatin (R2-GDP) schedule, as a translational substudy of the R2-GDP-GOTEL trial (EudraCT Number: 2014-001620-29), which included lenalidomide as an immunomodulator. Read More

View Article and Full-Text PDF

Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival.

Clin Lymphoma Myeloma Leuk 2021 May 11. Epub 2021 May 11.

Department of Haematology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Norway.

Anti-thymocyte globulin (ATG) is commonly used to prevent graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). To evaluate the impact of ATG as part of the GvHD prophylaxis in our institution, we report the outcome of 415 patients with matched unrelated donors (MUD) transplanted for hematological malignancies with or without ATG from 2005 to 2019 at Oslo University Hospital, Norway. The following groups were compared: (1) 154 patients transplanted with peripheral blood stem cells (PBSC) without ATG 2005-2014. Read More

View Article and Full-Text PDF

The Impact of Prior Salvage Treatment With Immune Checkpoint Inhibitors on Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single-Center Experience.

Clin Lymphoma Myeloma Leuk 2021 May 19. Epub 2021 May 19.

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

Introduction: The objective of the study was to assess the impact of the previous use of immune-checkpoint inhibitors (ICIs) on the clinical course of Hodgkin Lymphoma (HL) patients undergoing autologous hematopoietic stem cell transplantation (ASCT).

Methods: A single-center, retrospective chart review of adult HL patients who received ASCT from January 1, 2014, to December 31, 2019, was conducted. Primary endpoints included the length of stay (LOS) and the composite outcome of late-onset noninfectious fever (LONIF) or late-onset hypotension (LOH) requiring intravenous fluid (IVF) resuscitation. Read More

View Article and Full-Text PDF